FDA Reform Can Lift US Economy
Published March 15, 2013 by OSP
Changing the Food and Drug Administration's burdensome requirements for clinical trials could help double the number of new drug approvals, former FDA Commissioner Andrew von Eschenbach and University of Chicago public policy professor Tomas Philipson write. The inability of the Food and Drug Administration to keep pace with changes in medical science threatens both economic prosperity and public health. Adopting smaller, quicker adaptive studies with post-market oversight would mean greater innovation and a stronger economy.